133 related articles for article (PubMed ID: 38232337)
1. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).
Gronchi A; Palmerini E; Quagliuolo V; Martin Broto J; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz Beveridge R; Ferraresi V; Lugowska I; Pizzamiglio S; Verderio P; Fontana V; Donati DM; Palassini E; Sanfilippo R; Bianchi G; Bertuzzi A; Morosi C; Pasquali S; Stacchiotti S; Bagué S; Coindre JM; Miceli R; Dei Tos AP; Casali PG
J Clin Oncol; 2024 Mar; 42(8):898-906. PubMed ID: 38232337
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.
Gronchi A; Palmerini E; Quagliuolo V; Martin Broto J; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz Beveridge R; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Braglia L; Donati DM; Palassini E; Bianchi G; Marrari A; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
J Clin Oncol; 2020 Jul; 38(19):2178-2186. PubMed ID: 32421444
[TBL] [Abstract][Full Text] [Related]
3. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
Pasquali S; Palmerini E; Quagliuolo V; Martin-Broto J; Lopez-Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz-Beveridge R; Ferraresi V; Lugowska I; Infante G; Braglia L; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Bianchi G; Marrari A; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Miceli R; Casali PG; Gronchi A
Cancer; 2022 Jan; 128(1):85-93. PubMed ID: 34643947
[TBL] [Abstract][Full Text] [Related]
5. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
[TBL] [Abstract][Full Text] [Related]
7. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
Gronchi A; Frustaci S; Mercuri M; Martin J; Lopez-Pousa A; Verderio P; Mariani L; Valagussa P; Miceli R; Stacchiotti S; Dei Tos AP; De Paoli A; Longhi A; Poveda A; Quagliuolo V; Comandone A; Casali PG; Picci P
J Clin Oncol; 2012 Mar; 30(8):850-6. PubMed ID: 22312103
[TBL] [Abstract][Full Text] [Related]
8. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
Issels RD; Lindner LH; Verweij J; Wessalowski R; Reichardt P; Wust P; Ghadjar P; Hohenberger P; Angele M; Salat C; Vujaskovic Z; Daugaard S; Mella O; Mansmann U; Dürr HR; Knösel T; Abdel-Rahman S; Schmidt M; Hiddemann W; Jauch KW; Belka C; Gronchi A;
JAMA Oncol; 2018 Apr; 4(4):483-492. PubMed ID: 29450452
[TBL] [Abstract][Full Text] [Related]
9. Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study.
Bonvalot S; Wunder J; Gronchi A; Broto JM; Turcotte R; Rastrelli M; Papai Z; Radaelli S; Lindner LH; Shumelinsky F; Cubillo A; Rutkowski P; Demaire C; Strens D; Nalbantov G
Eur J Surg Oncol; 2021 Aug; 47(8):2166-2172. PubMed ID: 33676792
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis.
Chaigneau L; Jary M; Nerich V; Hervieu A; Aubry S; Charon Barra C; Meynard G; Neumann F; Kalbacher E; Isambert N
Oncology; 2022; 100(12):633-644. PubMed ID: 36283345
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial.
Sanfilippo R; Hindi N; Cruz Jurado J; Blay JY; Lopez-Pousa A; Italiano A; Alvarez R; Gutierrez A; Rincón-Perez I; Sangalli C; Pérez Aguiar JL; Romero J; Morosi C; Sunyach MP; Fabbroni C; Romagosa C; Ranchere-Vince D; Dei Tos AP; Casali PG; Martin-Broto J; Gronchi A
JAMA Oncol; 2023 May; 9(5):656-663. PubMed ID: 36995731
[TBL] [Abstract][Full Text] [Related]
12. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
[TBL] [Abstract][Full Text] [Related]
13. The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
Goy BW; Syed S; Padmanabhan A; Burchette RJ; Helmstedter CS
Radiother Oncol; 2021 Dec; 165():174-178. PubMed ID: 34758339
[TBL] [Abstract][Full Text] [Related]
14. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
Pasquali S; Pizzamiglio S; Touati N; Litiere S; Marreaud S; Kasper B; Gelderblom H; Stacchiotti S; Judson I; Dei Tos AP; Verderio P; Casali PG; Woll PJ; Gronchi A;
Eur J Cancer; 2019 Mar; 109():51-60. PubMed ID: 30690293
[TBL] [Abstract][Full Text] [Related]
15. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.
Gronchi A; Verderio P; De Paoli A; Ferraro A; Tendero O; Majò J; Martin J; Comandone A; Grignani G; Pizzamiglio S; Quagliuolo V; Picci P; Frustaci S; Dei Tos AP; Palassini E; Stacchiotti S; Ferrari S; Fiore M; Casali PG
Ann Oncol; 2013 Mar; 24(3):817-23. PubMed ID: 23110811
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group.
Grosso F; D'Ambrosio L; Zucchetti M; Ibrahim T; Tamberi S; Matteo C; Rulli E; Comandini D; Palmerini E; Baldi GG; DeCensi A; Bergaglio M; Marra D; Marchesi E; Siri G; D'Incalci M; Grignani G
Cancer; 2020 Nov; 126(21):4726-4734. PubMed ID: 32749681
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.
Le Cesne A; Blay JY; Cupissol D; Italiano A; Delcambre C; Penel N; Isambert N; Chevreau C; Bompas E; Bertucci F; Chaigneau L; Piperno-Neumann S; Salas S; Rios M; Guillemet C; Bay JO; Ray-Coquard I; Haddag L; Bonastre J; Kapso R; Fraslin A; Bouvet N; Mir O; Foulon S
Ann Oncol; 2021 Aug; 32(8):1034-1044. PubMed ID: 33932507
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy.
Mullen JT; Hornicek FJ; Harmon DC; Raskin KA; Chen YL; Szymonifka J; Yeap BY; Choy E; DeLaney TF; Nielsen GP
Cancer; 2014 Dec; 120(23):3676-82. PubMed ID: 25081640
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.
Gronchi A; Bui BN; Bonvalot S; Pilotti S; Ferrari S; Hohenberger P; Hohl RJ; Demetri GD; Le Cesne A; Lardelli P; Pérez I; Nieto A; Tercero JC; Alfaro V; Tamborini E; Blay JY
Ann Oncol; 2012 Mar; 23(3):771-776. PubMed ID: 21642514
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma.
Mannarino L; Craparotta I; Ballabio S; Frapolli R; Meroni M; Bello E; Panini N; Callari M; Sanfilippo R; Casali PG; Barisella M; Fabbroni C; Marchini S; D'Incalci M
Genomics; 2021 Sep; 113(5):3439-3448. PubMed ID: 34339817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
